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There is increased interest in cannabinoids for cancer pain management and legislative 
changes are in progress in many countries. Aim: to determine the beneficial and adverse 
effects of cannabis/cannabinoids compared to placebo/other active agents for the 
treatment of cancer-related pain in adults. 
 
Methods  
Systematic review and meta-analysis to identify randomised controlled trials of 
cannabinoids compared to placebo/other active agents for the treatment of cancer-related 
pain in adults to determine the effect on pain intensity (primary outcome) and adverse 
effects, including dropouts. Searches included Embase; MEDLINE; PsycINFO; Web of 
Science; ClinicalTrials.gov; Cochrane, and grey literature. Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. It was 
registered on PROSPERO (CRD42018107662).  
 
Results  
We identified 2805 unique records, of which 6 randomised controlled trials were included in 
this systematic review (n=1460 participants). Five studies were included in the meta-analysis 
(1442 participants). All had a low risk of bias. There was no difference between 
cannabinoids and placebo for the difference in the change in average numeric rating scale 
pain scores (mean difference -0.21 (-0.48, 0.07, p=0.14)); this remained when only Phase 3 
studies were meta-analysed: mean difference -0.02 (-0.21, 0.16, p=0.80). Cannabinoids had 
a higher risk of adverse events when compared to placebo, especially somnolence (OR=2.69, 
(1.54, 4.71), p<0.001) and dizziness (OR=1.58, (0.99, 2.51), p=0.05). No treatment-related 
deaths were reported. Dropouts and mortality rates were high.  
 
Conclusions  
Studies with a low risk of bias showed that for adults with advanced cancer, the addition of 
cannabinoids to opioids did not reduce cancer pain. 
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Introduction 
Cancer-related pain is common, occurring in up to 60% of patients undergoing anti-cancer 
therapy and 90% of those with advanced disease.1 There is an increased recent interest in 
cannabinoids (including cannabis) for pain management along with more permissive 
legislative changes in many countries.2, 3 The medicinal use of cannabis is already legal in 40 
countries and 29 US states.4 The World Health Organization guidelines for the 
pharmacological and radiotherapeutic management of cancer pain in adults and 
adolescents suggest that data analysis is needed on cannabinoids for cancer pain.5 
 
Patients with cancer use cannabinoids. An anonymous survey [2040 out of 3138 surveys 
(65%) were returned] in Canada showed that 356 (18%) patients reported cannabis use 
within the preceding 6 months. Of these, 80% acquired cannabis through friends and 46% of 
patients used it for cancer-related pain.6 In another anonymous survey of adult cancer 
patients in a cancer centre in a US state with legalised cannabis, random urine testing of 
sampled participants was used.7 The response rate was 34% (926/2737), of these 21% had 
used cannabis in the last month; most frequently for pain.7 
 
A systematic review was performed to identify all randomised controlled trials (RCTs) of 
cannabinoids compared to placebo or other active agents for the treatment of cancer-
related pain in adults. A meta-analysis was performed to determine cannabinoid 
effectiveness and adverse effects, including dropouts. A recent systematic review and meta-
analysis assessed the efficacy, tolerability, and safety of medical cannabis and cannabis-
based medicines for cancer pain reported very low quality evidence for a non-significant 
50% reduction in pain (p=0.82).8 This work supplements Hauser et al.8 The current 
systematic review has a broader search strategy, and authors were contacted to provide 
additional findings and information on study design. The primary outcome in this systematic 
review was the absolute change in mean pain intensity, which is a more sensitive outcome 
than a dichotomous outcome e.g. proportion of participants who report a pain relief of 50% 
or greater from baseline to end of study.9, 10 The aim was to determine the beneficial and 
adverse effects of cannabinoids compared to placebo or other active agents for the 




This systematic review was prepared according to the recommendations in the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses-Protocol (PRISMA-P) statement 
11 and was conducted/reported following an a priori protocol according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.12 
The review protocol was registered on PROSPERO (http://www.crd.york.ac.uk/PROSPERO) 




Strategies were devised to be inclusive of all potentially relevant studies using both Medical 
Subject Heading (MeSH) terms and text word searches to increase the search sensitivity. 
Terms for “cannabis/cannabinoids”, “cancer/neoplasms,” and “pain” were combined to 
identify relevant studies. The search terms for cannabinoids included individual drug names 
and generic terms “cannabinoids” and “cannabis”. The cancer search included the MeSH 
term “exp neoplasms/” and text word searches for synonyms for cancer. The “pain” search 
included terms and synonyms for pain. The Embase search strategy is included as a 
supplementary file. Search strategies from all other databases are available on request from 
the authors. 
 
In August 2018, the following electronic databases were searched: Embase (Ovid); Ovid 
MEDLINE(R) In-Process & Other Non-Indexed Citations; PsycINFO (Ovid); Conference 
Proceedings Citation Index–Science (Web Of Science; Thomson Reuters, New York City, NY); 
ClinicalTrials.gov (US NIH); ISRCTN registry (BMC); Cochrane Database of Systematic Reviews 
(Wiley); Cochrane Central Register of Controlled Trials (Wiley); and Database of Abstracts of 
Reviews of Effect (Wiley). All searches were repeated on the 1st August 2019 to ensure there 
were no further publications since the original searches.  
 
Searches were also conducted for grey literature using the following online databases: the 
Bielefeld Academic Search Engine (BASE) (https://www.base-search.net/), OpenGrey 
(http://www.opengrey.eu/), and Mednar (https://mednar.com/).   
 
Manual Searches 
In addition to the electronic search, reference lists from reviews on cannabis/cannabinoids 
to treat cancer pain were manually searched as were identified publications. Experts in the 
field were consulted to ensure that no articles were missed. Unpublished studies were also 
included in the search. When only a conference abstract was available and the full study 
was unpublished, authors were contacted to try to ascertain further information. No 
language date or publication type restrictions were applied to the search.  
 
Inclusion, exclusion, and selection criteria 
Studies were included if they were RCTs which assessed the effect of cannabinoids (THC: 
CBD, THC extract, nabiximols, Sativex, medical cannabis) compared to placebo or other 
active agents for the treatment of cancer-related pain in adults, with pain as the primary 
outcome (Table 1).  
 
Cochrane protocols determining studies for inclusion were followed, only including studies 
where the whole patient population had cancer pain. If this was not the case but results 
were presented separately for the cancer pain sub-group, the study and extracted data for 
the target subgroup were included. 
 
Studies were excluded if they did not meet the eligibility criteria (Table 1). Studies 
conducted in patients undergoing surgery, healthy volunteers, or animals were excluded 
from this systematic review as these groups have different cannabinoid usage (duration, 
administration schedule) compared with patients on cannabinoids for cancer pain. Studies 
other than RCTs potentially have too much bias to be included. Studies not having pain as 
the primary outcome were not included as they would not be designed or powered to 
determine the effect of cannabinoids on pain.  
 
Table 1: Eligibility criteria for inclusion of studies 
PICOS factors Inclusion criteria Exclusion criteria 
Population Patients with any type of cancer, 
including haematological and solid 
tumours 
Patients undergoing surgery, 
cannabis taken recreationally and 
cannabis in addiction, animal studies 
Intervention Multiple doses of cannabinoids via any 
route, for pain cancer-related 
management, (studies where only the 
minority of the exposed group received 
cannabis and cannabinoids were 
excluded) 
Single dose studies 
Comparison/control Any type of comparator, including 
placebo 
No comparator/control group 
Outcome Pain as the primary outcome Pain not the primary outcome 
Study design Randomised controlled trials (RCTs)  Cohort studies, prospective and 
retrospective observational 




Two authors (E.G.B. and J.W.B.) independently reviewed all titles and abstracts (in duplicate) 
to assess their relevance for inclusion. Full-text papers were retrieved for those fulfilling the 
criteria and also for those publications for which the ability to assess their eligibility could not 
be assessed on the basis of the titles and abstracts alone. E.G.B. and J.W.B. then 
independently assessed the full texts of all potentially relevant studies. 
Disagreement at all stages was resolved by consensus and with recourse to a third review 
author (M.I.B.). If a study was rejected at the full text stage, a reason was given. The results 
of these searches and selections are shown in the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) flow diagram (Figure 1).12 
 
Data extraction 
Two authors (E.G.B. and J.W.B.) independently extracted data from each included paper 
regarding study aims/objectives, design, patient population, intervention (cannabinoid used 
and dose), comparator, clinical outcome measures (eg, pain) and results (association 
between cannabinoid use and pain and reported adverse events). Disagreement was 
resolved by consensus and with recourse to a third review author (M.I.B.). When data were 





The primary outcome of interest was absolute mean change from baseline to the end of 
treatment in average pain on a Numerical Rating Scale (NRS). Secondary outcomes were 
adverse effects and study dropouts.  
 
Quality assessment of data 
Assessment of risk of study bias was independently assessed by two authors (E.G.B. and 
J.W.B.) using the Cochrane Collaboration risk of bias tool for RCTs which graded the risk of 
bias as high, low or unclear in 6 domains (Selection bias: Random sequence generation and 
Allocation concealment; Performance bias: Blinding of participant and personnel; Detection 
bias: Blinding of outcome assessment; Attrition bias: Incomplete outcome data; Reporting 
bias: Selective reporting). 14 Disagreement at all stages was resolved by consensus and with 
recourse to a third review author (M.I.B.). When this information was not available in the 
publication, authors were contacted.  
 
Data analysis 
For the meta-analysis, the difference in the mean change from the randomization baseline 
to the end of treatment in average pain NRS score was calculated and 95% confidence 
interval was calculated for each study. Data on the numbers of patients experiencing 
adverse events for each group, the odds ratio (OR) and 95% confidence interval (CI) were 
calculated for each study AE. The mean difference or OR’s were pooled using a fixed-effect 
model or random effects model [the Mantel-Haenszel method] and the corresponding 95% 
CIs were calculated.  
 
Where the analysis indicated significant heterogeneity a random effects model was chosen, 
otherwise a fixed effects model was applied. Statistical heterogeneity was assessed using 
the Cochran's Q test. The Cochran's Q tests the presence versus the absence of 
heterogeneity and the p value is stated. The I2 index describes the percentage of variation 
across studies that is due to heterogeneity rather than chance. Interpretation is as follows: 
low, moderate, and high to I2 values of 25%, 50%, and 75% respectively.15 The importance of 
the observed value of I2 depends on (i) magnitude and direction of effects and (ii) strength 
of evidence for heterogeneity (e.g. P value from the chi-squared test, or a confidence 
interval for I2). A funnel plot was used to test for publication bias.  
 
Results 
We identified 2805 unique records of which 6 RCTs were included in this systematic review. 
Due to the heterogeneous nature of some of these studies (in study design, duration/dose 
of cannabinoid administered, timing of outcome measurement), 5 studies were included in 
a meta-analysis (representing a total of 1442 participants) and 6 studies were included in a 
narrative analysis (representing a total of 1460 participants). 
 
Study characteristics 
From the 6 included RCTs (two were reported in a single publication), one was a small cross-
over pilot randomized study, two were phase 2 studies and three were phase 3 studies 
(Table 2). From the two early randomized double-blind phase 2 studies in patients with 
advanced cancer and pain unrelieved by opioids,16, 17 one reported that cannabinoids had 
analgesic effects,16 the primary outcome of the other was negative.17 Subsequent to these 
studies, three phase 3 placebo RCTs with a similar methodology have been reported. Data 
from two RCTs were reported in a single publication, with the primary efficacy endpoints 
(percent improvement [Study 1] and mean change [Study 2] in average daily pain NRS 
scores).18 Neither these nor the third RCT (primary endpoint: percent change in the average 
pain NRS score),19 reported a positive effect of nabiximols compared to placebo on their 
primary endpoints. These studies had a low risk of bias. 
 
The small cross-over pilot randomized study (n=18) assessed nabiximols vs placebo for use 
for treatment of chemotherapy-induced neuropathic pain and reported no statistically 
significant difference between nabiximols and placebo on the numeric rating scale for pain 
intensity: mean pretreatment score=6.75; and at the end of 4 weeks, nabiximols group 
score=6.00 whilst placebo group score=6.38.20 However, further analysis in 5 patients who 
responded to treatment showed an average decrease of 2.6 on an 11-point numeric rating 
scale for pain intensity.20  
 
Studies used a pump action oromucosal spray for medication delivery which used 1:1 
THC:CBD extract versus placebo. Some studies had additional arms eg THC extract.16 Dose 
titration differed between studies. Patients self-titrated to the optimal dose,16, 20 or were 
randomly assigned to different doses.17 In the phase 3 studies, patients titrated medication 
according to a pre-specified dose escalation protocol until they achieved pain relief, 
developed adverse events or reached the maximum dose of 10 sprays/day.18, 19 
 
Study quality 
Quality assessment of included studies was performed using the Cochrane Risk of Bias Tool 
(Supplementary Table 1). The studies included were at low risk of bias. Although the studies 
were funded (or had medication supplied) by industry, and publication bias is more 
common when most of the published studies are funded by industry, taken in the context of 
the results, these are overall negative studies making publication bias less likely. The funnel 
plot (Supplementary Figure 1) showed that distribution was roughly symmetrical, indicating 
that publication bias was not likely to be present. 
 
  
































































started as 1 
spray/day, 












average pain NRS 
score from 
baseline to end of 
treatment in the 
nabiximols and 
placebo groups 
were 10.7% vs. 
4.5% (P=0.0854) – 
ITT population 
Mean change from 
baseline to end of 
treatment: average 
pain NRS score, 










(P=0.4217) and daily 
total opioid dose -













Fallon 2017  
Study-1 

























and average pain 
numerical rating 
scale (NRS) scores 










Sativex (n=200)  
 
Started as 1 
spray/day, 











average daily pain 
NRS scores from 
baseline, Sativex 







for average pain NRS 
score 0.12, 95% CI -
0.18, 0.42 (P=0.434),  
for worse pain NRS 
score 0.11, 95% CI -
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effect: for daily 
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average pain NRS 
score -1.23, 95% CI -
9.05, 6.59 (P=0.757),  
for worse pain NRS 
score -0.32, 95% CI -
0.73, 0.09 (P=0.124) 
Estimated treatment 
effect: for daily 
maintenance opioid 
dose -8.93, 95% CI      
-19.69, 1.84 
(P=0.104), for daily 
breakthrough opioid 
dose 1.81, 95%CI         
-10.34, 13.96 
(P=0.769), for daily 
total opioid dose -
7.11, 95%CI -23.92, 
9.69 (P=0.405) 
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mean change in pain 
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groups in the use of 
regular opioids, or 
number of opioid 
used for 
breakthrough pain. 
Using the opioid 
composite score 
more patients in the 
nabiximol groups had 
a better responder 
profile compared to 
those in the placebo 
group (54% vs 43%, 
OR =1.54, 95% CI: 
0.95, 2.5; P=0.077). 
 











































Johnson 2010 Efficacy of 
THC:CBD  
and THC vs 
placebo, 
in relieving pain 



















177 patients with 
cancer pain (NRS 














(n =60) THC 












baseline in mean 
pain  







1.37 vs. -0.69).  
THC extract was a 
significant 










Twice as many 
patients taking 
THC:CBD showed a 
reduction of 
more than 30% from 
baseline pain NRS 
score when 
compared with 
placebo (23 [43%] vs. 
12 [21%]). The OR of 
responders between 
THC:CBD and 
placebo was 2.81 




similar to placebo (12 
[23%] vs. 12 [21%]).  
 
Number of days of 
use of breakthrough 
medication used was 
similar amongst all 
groups (p=0.70). 
There was a 
reduction observed 
in the mean number 
of daily doses of all 
breakthrough 
medication (THC:CBD 
-0.19; THC -0.14, 
Placebo -0.15) but 
the difference in 
change from baseline 







































Change in pain intensity was the primary outcome of interest in this systematic review. 
Change in pain intensity was the primary outcome in the studies, Johnson et al,16 Fallon et 
al,18  Lichtman et al 19 and a secondary outcome in Portenoy et al.17 Lynch et al measured 
change in the numeric rating scale for pain intensity and reported that there was no 
statistically significant difference between the treatment and the placebo groups but as this 
study only included people with chronic neuropathic pain and was a small exploratory 
study, it was not included in the meta-analysis.20  
 
The meta-analysis is shown in Figure 2. There was no difference between cannabinoids and 
placebo for the difference in the change in average NRS pain scores: mean difference -0.21 
(-0.48, 0.07, p=0.14). Including only Phase 3 studies in the meta-analysis, there was no 
benefit from cannabinoid use: mean difference -0.02 (-0.21, 0.16, p=0.80) (Figure 3).18, 19 
The change in pain intensity was a secondary outcome in Portenoy et al; their primary 
outcome (30% reduction in baseline pain) was not statistically different between 
cannabinoids and placebo (P=0.59).17 In Portenoy et al, data was not available for the mean 
pain difference of all three doses combined,17 so only the low dose (1-4 sprays) was used in 




All studies reported on adverse events (Table 3). Dizziness, nausea, vomiting, somnolence 
and fatigue were the main reported adverse events. In general cannabinoids were reported 
to have a higher risk of adverse events compared to placebo. Fallon et al, Lichtman et al and 
Portenoy et al reported only the adverse events in 5% of patients.17, 18, 19 In Johnson et al, 
it is only those reported in 3 or more patients.16 Lynch et al reported more adverse events 
compared to placebo, but as this study only included people with chronic neuropathic pain 
and was a small pilot study, it was not included in the meta-analysis.20 In the meta-analysis 




Table 3: Treatment-emergent adverse events (TEAE) 
 Total Dizziness Nausea/ Vomiting Somnolence 
/Fatigue 
Lichtman 2018 * Nabiximols vs 
placebo: 70 




placebo:  15 (7.5%) 
vs 5 (2.5%) 
Nabiximols vs 
placebo: nausea 
17 (8.5%) vs 10 (5.1%) 
 Occurred at an 
incidence of 
<5% within each 
treatment group 




(32.2%) vs  41 
(20.7%)  
Nabiximols vs 
placebo: 15 (7.5%) 
vs 6 (3.0%) 
Nabiximols vs 
placebo: nausea 10 




(9.0%) vs 6 (3.0%)  





128 (31.7%) Dizziness 21 (5.2%) Nausea 21 (5.2%) somnolence 42 
(10.4%) 
Fallon 2017  
Study-2 double-





Occurred at an 
incidence of 
<5% within either 
treatment group 
Occurred at an 
incidence of 





(5.8%) vs 0 (0.0%)  
 
Lynch 2014 Not reported Nabiximols vs 
placebo: 








7 (77.8%) vs 0  
Portenoy 2012 Number of TEAE 
Nabiximols at a 
low dose 270, 
medium dose 
311, high dose 
334, all 915, 
placebo 215. 
 
Serious TEAE: low 
dose Nabiximols 
34 (37.4%), 
medium dose 18 
(20.7%), high 






10 (11%), medium 
dose 21 (24.1%), 
high dose (20 
(22.2%) vs placebo 
12 (13.2%) 
** Nabiximols for 
nausea 
low dose 16 (17.6%), 
medium dose 18 
(20.7%), high dose 25 
(27.8%) vs placebo 12 
(13.2%) 
 
** Nabiximols for 
vomiting 
low dose 9 (9.9%), 
medium dose 14 
(16.1%),  high dose 19 
(21.1%) vs placebo 7 
(7.7%) 
 
** Nabiximols for 
somnolence 
low dose 8 (8.8%), 
medium dose 16 
(18.4%), high dose 
15 (16.7%) vs 
placebo 4 (4.4%) 
 
** Nabiximols for 
fatigue 
low dose 4 (4.4%), 
medium dose 4 
(4.6%), high dose 5 




From all patients: 
106 (60%) 
THC:CBD 7 (12%), 
THC extract 7 (12%) 
vs placebo 3 (5%) 
Nausea: 
THC:CBD 6 (10%), THC 
extract 4 (7%) vs 
placebo 4 (7%) 
 
Vomiting: 
THC:CBD 3 (5%), THC 
extract 4 (7%) vs 
placebo 2 (3%) 
Somnolence: 
THC:CBD 8 (13%), 
THC extract 8 (14%) 
vs placebo (6 (10%) 
*Treatment-emergent adverse events in ≤ 5% of patients 
** Treatment-emergent adverse events reported by ≥ 5% of patients 
***Treatment-Related Adverse Events (Reported by ≥3 patients)
The meta-analysis shows a higher odds of somnolence (OR=2.69, (1.54, 4.71), p<0.001) and 
dizziness (OR=1.58, (0.99, 2.51), p=0.05) in the cannabinoid group (Figure 4).16-19 There was 
also a higher odds of nausea (OR=1.41, (0.97, 2.05), p=0.08) and vomiting in the cannabinoid 
group (OR=1.34, (0.85, 2.11, p=0.21), but these were not statistically significant (Figure 4).16-
19 
 
Dropouts due to adverse events 
In Johnson et al, dropouts due to adverse events were 16.7% in the THC:CBD group and 5% 
in the placebo group.16 In Portenoy et al, adverse event discontinuations were dose related; 
19.8% in all patients on nabiximols and 17.6% in the placebo group.17 In study 1 by Fallon et 
al, 19% sativex patients and 14.6% placebo patients discontinued due to adverse events.18 In 
study-2 by Fallon et al, during the 2-week single-blind Sativex titration period, 17.5% 
patients discontinued sativex due to adverse events.18 In the treatment period, 20.4% 
withdrew from the sativex group and 12.6% withdrew from the placebo group.18 In 
Lichtman et al, discontinuation due to adverse events was 20.1% in the sativex group and 
17.7% in the placebo group.19 No treatment-related deaths were reported in any study. 
Figure 5 shows the dropouts due to adverse events which shows a higher odds of dropouts 
due to adverse events in the cannabinoid group (OR = 1.33, (0.95, 1.85, p=0.10), but not 
statistically significant. In the meta-analysis only the low dose (1-4 sprays) was used from 





Studies with a low risk of bias showed that for adults with advanced cancer, the addition of 
cannabinoids to opioids did not reduce cancer pain compared to placebo. This work 
complements and builds on the systematic review by Hauser et al.8 Although the same 
overall conclusions were attained, this systematic review and meta-analysis is based on 
additional methodological information and thus supported by higher-quality evidence (as 
included studies were deemed to have lower risk of bias). Furthermore the primary 
outcome in this systematic review is a more sensitive outcome to detect minimal changes in 
pain.9 This systematic review provides good evidence that cannabinoids do not have a role 
in cancer-related pain.   
 
In all the included RCTs, pain was the primary reason for administering cannabinoids and 
change in pain score or pain intensity was the primary outcome. Five RCTs were included in 
the meta-analysis (n=1442) where cannabinoids were given as an adjuvant treatment in 
addition to their existing stable dose of opioids. In the meta-analysis, the two phase 2 
studies and three phase 3 studies, included patients with chronic cancer pain (average pain 
duration of all studies of 1.2-2.0 years), with an average pain ≥4 and ≤8 on 0-10 NRS pain 
score, were on regular opioids, randomized to the same THC:CBD medication and had a 
placebo comparator.  
 
Five trials from four publications in the 1970s (including a total of 128 participants) were 
excluded as these were single dose studies, assessing short-term effects of cannabinoids at 
6-7 hours.21-24 Four of these studies evaluated delta-v-tetrahydrocannabinol (THC) or 
nitrogen-containing benzopyran derivative, modification of delta-1-trans-
tetrahydrocannabinol (NIB).21, 22, 24 The 5th study used the cannabinoid 
benzopyranoperidine.23 Of these five single dose studies assessing efficacy at 6-7 hours, 
three used THC or NIB and reported no different in efficacy compared to codeine.21, 22, 24 The 
5th study used the cannabinoid benzopyranoperidine and reported that about 30% of 
patients had increased pain intensity with this drug.23  
 
Side effects 
Cannabinoids are associated with short-term adverse effects including drowsiness, 
dizziness, confusion, hallucinations, euphoria, nausea and vomiting, diarrhoea.25 A 
systematic review evaluating the adverse effects of medical cannabinoids reported patients 
using medical cannabinoids had 1.86 higher risk of non-serious adverse effects compared to 
controls whilst there was no significant difference between serious adverse effects.26  
Our analysis echoed this, showing that in general cannabinoids were reported to have a 
higher risk of adverse events compared to placebo with somnolence and dizziness reaching 
statistical significance. 
 
Strengths and limitations  
This is a rigorously conducted systematic review that included “grey” literature and authors 
were contacted when data and methodological information was not included in the 
publication. This enabled the included studies to be considered at low risk of bias. The 
studies included were RCTs that assessed clinically relevant cannabinoids as an adjuvant to 
opioid medications in patients with advanced cancer that had mixed aetiologies of pain due 
to their cancer. Change in pain score was used as the primary outcome to assess if 
cannabinoids had an effect on pain as this is more sensitive to changes compared to 30% or 
50% decrease in pain. 
 
Despite the detailed search strategy, it is possible that not all relevant studies were included. 
There were inconsistences between studies in the patients included, the interventions, 
comparators and outcomes. In the meta-analysis, a secondary outcome was used for 
Portenoy et al (as this was the primary outcome for this systematic review).16, 17  
 
The included studies had several potential limitations. Self-reported NRS pain score might 
not be the best measure for such trials, as this simple instrument does not capture the 
complexity of pain especially when it has been long-standing problem. The fidelity of the 
use of the oromucosal spray, which affects absorption and pharmacokinetic factors, was not 
assessed and this might also affect the effectiveness of the medication used and the 
outcome measured.  Some of the included studies had kept the maintenance doses of 
opioid and other medications the same throughout the trial, ways to decrease doses when 
appropriate should be considered as this might also have an impact on adverse effects. The 
negative results from some of the RCTs could be due to a relatively high number of patient 
withdrawals and high mortality rate.16-19 Publication bias is more common when most of the 
published studies are funded by industry. However, the primary outcome for most of these 
studies was negative, making publication bias less likely for these studies. Aside from lack of 
therapeutic efficacy, the negative results from some of the RCTs could also be due to a 
relatively high number of patient withdrawals from studies, and also high mortality rate and 




For a medication to be useful, there needs to be a net overall benefit, with the positive 
effects (analgesia) outweighing adverse effects. None of the included phase 3 studies show 
benefit of cannabinoids. One of the phase 2 studies showed benefit in their primary 
outcome,16 the other was negative in its primary outcome, although a secondary outcome 
was positive.17 When statistically pooled there was no decrease in pain score from 
cannabinoids. There are however significant adverse effects and dropouts reported from 
cannabinoids. Based on evidence with a low risk of bias, cannabinoids cannot be 
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Figure 1: PRISMA flow diagram  
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Web of Science 382
ClinicalTrials.gov 124
ISRCTN registry 7 
Cochrane Database of Systematic Reviews (protocols) 4
Cochrane Database of Systematic Reviews 37
Cochrane Central Register of Controlled Trials 119
Database of Abstracts of Reviews of Effect 10
Bielefeld Academic Search Engine (BASE) 294
OpenGrey 19
Mednar 533
































Figure 4: Forest plots for the main adverse effects for the phase 2 and 3 studies. (Fallon 






Figure 5: Dropouts due to adverse events 
 
